Traditionally, the normal PSA level that is acceptable as the basis for biopsy in phase 3 clinical studies of early prostate cancer screening is <4.0 ng/mL [20], and this serves as an important indicator for judging the presence or absence of prostate cancer via LFIA [23,24]. This evidence concerns the gene KLK3 and prostate cancer.